The decline in Structure Therapeutics' stock price is a direct reaction to the announcement regarding their drug development program. Such updates are critical to investors as they can indicate progress or setbacks in the drug's path to market, which in turn can affect the company's future revenue and growth prospects. The negative market reaction suggests that the update may have contained information that investors perceived as unfavorable, although the specifics of the update are not provided in the article.